Adimmune Corporation

4142

TW0004142005

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
28.7 ^TWD	+0.70%		+1.77%	-13.42%

06-21	Adimmune Corporation Appoints Mei-Ling Hsiao as Member of the Audit Committee	CI
06-21	Adimmune Corporation Elects Mei-Ling Hsiao as Director	CI

Adimmune Corporation Elects Mei-Ling Hsiao as Director

June 21, 2024 at 06:06 am

Adimmune Corporation at its 2024 regular shareholders meeting held on June 21, 2024, Elections for board of directors and supervisors: Addition of one independent director. List of elected independent director: Mei-Ling Hsiao. The term of the new independent director from June 21, 2024 to June 28, 2025.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MSCI TAIWAN (STRD)	849.5 USD	-1.32%	+0.02%	-
	ADIMMUNE CORPORATION	28.7 TWD	+0.70%	+1.77%	370M

Latest news about Adimmune Corporation

Adimmune Corporation Appoints Mei-Ling Hsiao as Member of the Audit Committee	06-21	CI
Adimmune Corporation Elects Mei-Ling Hsiao as Director	06-21	CI
Adimmune Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
An unknown buyer acquire 2.14% stake in Adimmune Corporation from BioEngine Technology Development Inc. for NTD300 million.	02-04	CI
Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Adimmune Corporation Announces Change in Representative of its Institutional Director	11-01	CI
Adimmune Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Adimmune Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Clover Bio Signs Exclusive Deal to Distribute Influenza Vaccine in China; Shares Climb 3%	20/02/23	MT
Clover Biopharmaceuticals, Ltd. Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China	19/02/23	CI
Tranche Update on Adimmune Corporation's Equity Buyback Plan announced on November 11, 2022.	21/11/22	CI
Adimmune Corporation's Equity Buyback announced on November 11, 2022 has closed with the repurchase of 5,000,000 shares, representing 1.17% for TWD 182.07 million.	20/11/22	CI
Adimmune Turns Profitable in January-September	14/11/22	MT
Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	13/11/22	CI
Adimmune Corporation announces an Equity Buyback for 5,000,000 shares.	11/11/22	CI
Adimmune Corporation authorizes a Buyback Plan.	10/11/22	CI
Adimmune Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Tranche Update on Adimmune Corporation's Equity Buyback Plan announced on June 9, 2022.	09/08/22	CI
Adimmune Corporation's Equity Buyback announced on June 9, 2022, has closed with 3,000,000 shares, representing 0.7% for TWD 110.56 million.	08/08/22	CI
Adimmune Upbeat on H2 Revenue	27/07/22	MT
Adimmune Corporation announces an Equity Buyback for 3,000,000 shares, representing 0.7% for TWD 1,528.09 million.	09/06/22	CI
Adimmune Corporation authorizes a Buyback Plan.	08/06/22	CI
Adimmune Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI

Chart Adimmune Corporation

Duration

Period

More charts

Company Profile

ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ADIMMUNE CORPORATION	-13.42%	370M
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.34B
BIOGEN INC.	-13.04%	32.76B
UCB	+80.67%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.31B
INCYTE CORPORATION	+1.93%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.23B
ALTEOGEN INC.	+177.16%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	-0.45%	8.97B

Biopharmaceuticals